Johnson & Johnson, who manufactures and sells the anti-psychotic drug Risperdall, through their subsidiary, Janssen Pharmaceuticals, has agreed to one of the largest healthcare fraud penalties by paying 2.2 billion dollars. This settlement was the result of an investigation by the United States Department of Justice into the illegal marketing of the drugs Risperdal, Invega and Natrecor. The allegations were that the J&J company, Janssen, was promoting and selling the drug for the use of elderly patients for dementia and for attention deficit disorder on children. In April of 2012 the State of Arkansas won a 1.1 billion dollar lawsuit against J&J and Janssen over Risperdal in which it was alleged that the company mislead the public by hiding risks of the drug.
“This payment is further proof that these drug companies were exposing the most vulnerable, the elderly and children, to risks but that they were doing with the knowledge of the devastating effects that the side effects could have.”
Sean Keith Drug and Device Injury Attorney
There are hundreds of lawsuits against J&J by patients over the drug Risperdal for causing the condition known as gynecomastia or male breast growth alleged to be due to the use of the Risperdal. Already several of these cases have been settled with the company. The lawsuits also allege that Johnson & Johnson concealed evidence that Risperdal could cause male breast growth and that they had improperly marketed the antipsychotic drug for use in children.
Sean Keith, an attorney who represents clients across Arkansas, Oklahoma, Kansas, Missouri, Texas in drug and device cases is investigating these cases and is offering free case reviews to anyone who has developed gynecomastia or male breast growth due to the use of Risperdal. Contact him by either clicking on the contact us button or by calling 1800-698-3644.